[
    {
        "@id": "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#provenance",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#assertion",
                "http://www.w3.org/ns/prov#wasAttributedTo": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#Head",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE",
                "http://www.nanopub.org/nschema#hasAssertion": [
                    {
                        "@id": "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#assertion"
                    }
                ],
                "http://www.nanopub.org/nschema#hasProvenance": [
                    {
                        "@id": "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#provenance"
                    }
                ],
                "http://www.nanopub.org/nschema#hasPublicationInfo": [
                    {
                        "@id": "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#pubinfo"
                    }
                ],
                "@type": [
                    "http://www.nanopub.org/nschema#Nanopublication"
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#pubinfo",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#sig",
                "http://purl.org/nanopub/x/hasAlgorithm": [
                    {
                        "@value": "RSA"
                    }
                ],
                "http://purl.org/nanopub/x/hasPublicKey": [
                    {
                        "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
                    }
                ],
                "http://purl.org/nanopub/x/hasSignature": [
                    {
                        "@value": "a7/H+AvkeDkIrMj9ymhEqSr5x182wkUxWk22OLLMrpAny1MY/RjC48HiSljXs5Qs8K8ioxbAQLMZU8St2Xf2s1c+/5ngtPrGymx5WDaxlQpIeuPLb7aKrNTYso/ePXP79LzpW3zvtcdI0r3u9wNH6ThPcyVIqpZHe3mBMeBQrO8="
                    }
                ],
                "http://purl.org/nanopub/x/hasSignatureTarget": [
                    {
                        "@id": "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE",
                "http://purl.org/dc/terms/created": [
                    {
                        "@value": "2021-08-23T18:39:25.828+02:00",
                        "@type": "http://www.w3.org/2001/XMLSchema#dateTime"
                    }
                ],
                "http://purl.org/dc/terms/creator": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate": [
                    {
                        "@id": "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate": [
                    {
                        "@id": "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [
                    {
                        "@id": "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#assertion",
        "@graph": [
            {
                "@id": "http://purl.obolibrary.org/obo/DOID_224",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Disease"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#association",
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [
                    {
                        "@id": "http://purl.obolibrary.org/obo/DOID_224"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/treats"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [
                    {
                        "@id": "https://identifiers.org/drugbank:DB06209"
                    }
                ],
                "@type": [
                    "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement"
                ],
                "http://www.w3.org/2000/01/rdf-schema#label": [
                    {
                        "@value": "\"* Active pathological bleeding ( 4.1 4.2 4.3 Prasugrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage  [see Warnings and Precautions ( 5.1 6.1 Prasugrel tablets is contraindicated in patients with a history of prior transient ischemic attack (TIA) or stroke. In TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel), patients with a history of TIA or ischemic stroke (>3 months prior to enrollment) had a higher rate of stroke on Prasugrel tablets (6.5%; of which 4.2% were thrombotic stroke and 2.3% were intracranial hemorrhage [ICH]) than on clopidogrel (1.2%; all thrombotic). In patients without such a history, the incidence of stroke was 0.9% (0.2% ICH) and 1.0% (0.3% ICH) with Prasugrel tablets and clopidogrel, respectively. Patients with a history of ischemic stroke within 3 months of screening and patients with a history of hemorrhagic stroke at any time were excluded from TRITON-TIMI 38. Patients who experience a stroke or TIA while on Prasugrel tablets generally should have therapy discontinued  [see Adverse Reactions ( 6.1 14 Prasugrel tablets is contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to prasugrel or any component of the product  [see Adverse Reactions ( 6.2\""
                    }
                ],
                "https://w3id.org/biolink/vocab/provided_by": [
                    {
                        "@id": "https://w3id.org/um/NeuroDKG"
                    }
                ],
                "https://w3id.org/biolink/vocab/relation": [
                    {
                        "@id": "https://schema.org/MedicalContraindication"
                    }
                ]
            },
            {
                "@id": "https://identifiers.org/drugbank:DB06209",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Drug"
                    }
                ]
            }
        ]
    }
]